213 related articles for article (PubMed ID: 32862848)
21. Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm.
Fend F; Horn T; Koch I; Vela T; Orazi A
Leuk Res; 2008 Dec; 32(12):1931-5. PubMed ID: 18555525
[TBL] [Abstract][Full Text] [Related]
22. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.
Turakhia SK; Murugesan G; Cotta CV; Theil KS
J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830
[TBL] [Abstract][Full Text] [Related]
23. Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.
Tefferi A
J Cell Mol Med; 2009 Feb; 13(2):215-37. PubMed ID: 19175693
[TBL] [Abstract][Full Text] [Related]
24. Haematological differences between chronic granulocytic leukaemia, atypical chronic myeloid leukaemia, and chronic myelomonocytic leukaemia.
Galton DA
Leuk Lymphoma; 1992 Aug; 7(5-6):343-50. PubMed ID: 1493435
[TBL] [Abstract][Full Text] [Related]
25. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
26. Trametinib: Could It Be a Promising Drug to Treat Atypical Chronic Myeloid Leukemia?
Elsayed M; Harry S; Nanua S; Zaidi S; Habib MH; Raza S
Cureus; 2022 Jul; 14(7):e26619. PubMed ID: 35949766
[TBL] [Abstract][Full Text] [Related]
27. [The usefulness of the bcr/abl rearrangement in the diagnosis and evolution of chronic myeloid leukemia].
González FA; Villegas A; Ferro MT; San Román C; Sáez I; López M; del Potro E; Alvarez A; Martínez R; Díaz Madiavilla J
Med Clin (Barc); 1993 Oct; 101(14):521-4. PubMed ID: 8231395
[TBL] [Abstract][Full Text] [Related]
28. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
Patnaik MM; Lasho T
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):460-464. PubMed ID: 33275673
[TBL] [Abstract][Full Text] [Related]
29. Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. The Groupe Français de Cytogénétique Hématologique.
Martiat P; Michaux JL; Rodhain J
Blood; 1991 Jul; 78(1):205-11. PubMed ID: 2070054
[TBL] [Abstract][Full Text] [Related]
30. Further evidence for the molecular heterogeneity of chronic myeloid leukemia.
Hernandez A; Corral L; Muñiz A; Alaez C; Espinosa E; Martinez G; Hernandez P
Ann Hematol; 1991 Jun; 62(6):217-20. PubMed ID: 1854884
[TBL] [Abstract][Full Text] [Related]
31. A Case Report of
Ali EAH; Al-Akiki S; Yassin MA
Case Rep Oncol; 2021; 14(1):690-694. PubMed ID: 34054462
[TBL] [Abstract][Full Text] [Related]
32. Oncogenes in myeloproliferative disorders.
Tefferi A; Gilliland DG
Cell Cycle; 2007 Mar; 6(5):550-66. PubMed ID: 17351342
[TBL] [Abstract][Full Text] [Related]
33. A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia.
Chung A; Hou Y; Ohgami RS; Von Gehr A; Fisk DG; Roskin KM; Li X; Gojenola L; Bangs CD; Arber DA; Fire AZ; Cherry AM; Zehnder JL; Gotlib J; Merker JD
Cancer Genet; 2017 Oct; 216-217():10-15. PubMed ID: 29025582
[TBL] [Abstract][Full Text] [Related]
34. Heterogeneous features of Ph-negative CML--possible existence of Ph-negative, bcr-rearrangement-negative CML.
Kato Y; Sawada H; Tashima M; Yumoto Y; Okuda T; Ueda T; Yamagishi M; Uchino H
Nihon Ketsueki Gakkai Zasshi; 1989 Sep; 52(6):1004-12. PubMed ID: 2588950
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Implications of Derivative Chromosome 9 Deletions in Patients with Advanced-Stage Chronic Myelogenous Leukemia.
Chandran RK; Geetha N; Sakthivel KM; Aswathy CG; Gopinath P; Nair JKKM; Sreedharan H
J Environ Pathol Toxicol Oncol; 2018; 37(2):117-126. PubMed ID: 30055547
[TBL] [Abstract][Full Text] [Related]
36. Deactylase inhibition in myeloproliferative neoplasms.
Mithraprabhu S; Grigoriadis G; Khong T; Spencer A
Invest New Drugs; 2010 Dec; 28 Suppl 1(Suppl 1):S50-7. PubMed ID: 21127942
[TBL] [Abstract][Full Text] [Related]
37. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
[TBL] [Abstract][Full Text] [Related]
38. A Rare Case of Systemic Mastocytosis with Associated Hematologic Neoplasm (SM-AHN) Involving Chronic Myeloid Leukemia: A Case Report and Literature Review.
Ibrahim FA; Abdulla MAJ; Soliman D; Al Sabbagh A; Nawaz Z; Akiki SJ; Shwaylia H; Yassin MA
Am J Case Rep; 2020 May; 21():e923354. PubMed ID: 32398637
[TBL] [Abstract][Full Text] [Related]
39. Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview.
Kuendgen A; Kasprzak A; Germing U
Front Oncol; 2021; 11():778741. PubMed ID: 34869027
[TBL] [Abstract][Full Text] [Related]
40. [BCR-ABL1 negative chronic myeloid leukemia: report of two cases].
Figueroa-Faúndez F; Vidal-Rojas C; Briones-Muñoz V; Chandía-Cabas M
Rev Med Chil; 2022 Mar; 150(3):397-401. PubMed ID: 36156725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
